{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:44:58Z","timestamp":1776228298111,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2014,7,9]],"date-time":"2014-07-09T00:00:00Z","timestamp":1404864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovascular Therapeutics"],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Oxidative stress plays an important role in atherosclerosis. Both F2\u2010isoprostane (8\u2010iso\u2010<jats:styled-content style=\"fixed-case\">PGF<\/jats:styled-content>2a) and oxidized low\u2010density lipoprotein (ox\u2010<jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content>) have emerged as biomarkers of oxidative stress and have been proposed as useful biomarkers that could potentially be used as indicators of cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prespecified analysis of a prospective, randomized, open\u2010label, blinded endpoint (<jats:styled-content style=\"fixed-case\">PROBE<\/jats:styled-content>) study (ClinicalTrials.gov identifier: <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>01010516). Patients (N\u00a0=\u00a0100) with mixed dyslipidemia on a standard statin dose (10\u201340\u00a0mg simvastatin or 10\u201320\u00a0mg atorvastatin or 5\u201310\u00a0mg rosuvastatin) who had not achieved lipid targets were randomized to switch to the highest dose of rosuvastatin (40\u00a0mg\/day) or to add\u2010on\u2010statin extended release nicotinic acid (<jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content>)\/laropiprant (<jats:styled-content style=\"fixed-case\">LRPT<\/jats:styled-content>) (1000\/20\u00a0mg\/day for the first 4\u00a0weeks followed by 2000\/40\u00a0mg\/day for the next 8\u00a0weeks) or to add\u2010on\u2010statin micronized fenofibrate (200\u00a0mg\/day) for a total of 3\u00a0months. Levels of plasma and urine F2\u2010isoprostane and plasma ox\u2010<jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content> were assessed at baseline and 3\u00a0months later.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Plasma F2\u2010isoprostane levels decreased similarly in all groups. On the other hand, both ox\u2010<jats:styled-content style=\"fixed-case\">LDL<\/jats:styled-content> and urine F2\u2010isoprostane levels decreased similarly in the add\u2010on <jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LRPT<\/jats:styled-content> and rosuvastatin monotherapy group, while a less pronounced decrease was observed in the add\u2010on fenofibrate group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>All treatment interventions reduced the concentration of the assessed oxidative stress markers, but the reduction was more pronounced in the add\u2010on <jats:styled-content style=\"fixed-case\">ER<\/jats:styled-content>\u2010<jats:styled-content style=\"fixed-case\">NA<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">LRPT<\/jats:styled-content> and rosuvastatin monotherapy groups, compared with add\u2010on fenofibrate. Specifically designed studies should address the abovementioned risk factors modulation in terms of cardiovascular risk.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1755-5922.12072","type":"journal-article","created":{"date-parts":[[2014,3,12]],"date-time":"2014-03-12T07:58:58Z","timestamp":1394611138000},"page":"139-146","source":"Crossref","is-referenced-by-count":16,"title":["Effect of Switch to the Highest Dose of Rosuvastatin Versus Add\u2010on\u2010Statin Fenofibrate Versus Add\u2010on\u2010Statin Nicotinic Acid\/Laropiprant on Oxidative Stress Markers in Patients with Mixed Dyslipidemia"],"prefix":"10.1111","volume":"32","author":[{"given":"Anastazia","family":"Kei","sequence":"first","affiliation":[{"name":"Department of Internal Medicine University of Ioannina Medical School Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantinos","family":"Tellis","sequence":"additional","affiliation":[{"name":"Department of Biochemistry \u2013 Clinical Chemistry University of Ioannina Chemistry School Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Liberopoulos","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Ioannina Medical School Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandros","family":"Tselepis","sequence":"additional","affiliation":[{"name":"Department of Biochemistry \u2013 Clinical Chemistry University of Ioannina Chemistry School Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moses","family":"Elisaf","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Ioannina Medical School Ioannina Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67394-1"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248408318628"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000150649.39934.13"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133444.17867.56"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14234-1"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12098"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12095"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11745-013-3826-y"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3182548c28"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2174\/157016111796197279"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.112.203661"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.591383"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.11.022"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/1074248406296108"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650639"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600109-JLR200"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00264-6"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(02)00017-1"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.23.9383"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000152605.64964.c0"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.03.052"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000021150.63480.CD"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.21.5.844"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043175"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90926-T"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02568.x"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00700-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2005.12.002"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.03.001"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.2217\/fca.10.86"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-008-9309-1"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1152\/japplphysiol.00969.2013"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc4501.098468"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/hc4401.098467"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2760(90)90314-N"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118359"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.06.006"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400549200"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.4239\/wjd.v4.i6.365"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1080\/15257770802138558"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2012.00030"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mca.0000131573.31966.34"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.13.jpc60002"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011090"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht055"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107579"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s203"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110874"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"}],"container-title":["Cardiovascular Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1755-5922.12072","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1755-5922.12072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T16:21:11Z","timestamp":1696263671000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1755-5922.12072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,9]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["10.1111\/1755-5922.12072"],"URL":"https:\/\/doi.org\/10.1111\/1755-5922.12072","archive":["Portico"],"relation":{},"ISSN":["1755-5914","1755-5922"],"issn-type":[{"value":"1755-5914","type":"print"},{"value":"1755-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,9]]}}}